Ignite Creation Date:
2024-05-05 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00164801
Status:
TERMINATED
Last Update Posted:
2008-03-26
First Post:
2005-09-09
Brief Title:
Effect of GABAB Agonist on Visceral Hyperalgesia in NCCP patientsChinese
Sponsor:
Chinese University of Hong Kong
Organization:
Chinese University of Hong Kong
Study Overview
Official Title:
Is Visceral Hyperalgesia the Culprit of Noncardiac Chest Pain in Chinese Part 2 Effect of GABAB Agonist on Visceral Hyperalgesia in NCCP Patients
Status:
TERMINATED
Status Verified Date:
2008-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Funding ended
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The effect of baclofen GABAB agonist diltiazem muscle relaxant and placebo will be compared in a double-blinded randomized study for the treatment of NCCP Cerebral cortical brainstem and spinal evoked potentials before and after treatment will be evaluated Results of this study will shed lights on pathogenesis and treatment of NCCP in ChineseWe hypothesize that Baclofen alleviates visceral hyperalgesia in NCCP patients by suppressing afferent sensory pathway
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None